An interventional study of Automated Mobile Contingency Management (CM) and Standard Care (SC) in Smoking Cessation, sponsored by University of Oklahoma. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Oklahoma · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Smoking Cessation by University of Oklahoma — 6 open to participants now, 7 under way, 1 of them phase 3. Smoking Cessation · University of Oklahoma.
Among the 26 studies in Smoking Cessation by University of Oklahoma, this one is the 3rd largest by enrollment, is one of 5 that started in 2022, is one of 17 with no phase, and was the 15th registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →6 of the 26 studies in Smoking Cessation by University of Oklahoma are open now, in 2 countries. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18+ · Healthy volunteers
University of Oklahoma · Sites in United States
Ages 18+ · Healthy volunteers
University of Oklahoma · Sites in United States
Ages 18–100 · Healthy volunteers
University of Oklahoma · Sites in United States
Ages 18+ · Healthy volunteers
University of Oklahoma · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 2 · Phase 4 1
First in 2013; this study’s year is marked. 5 started in 2022.
This study's enrollment of 532 is above the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 81 across the 26 interventional studies. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Oklahoma is the lead sponsor of 432 studies on the registry; 98 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.
1 of the studies in Smoking Cessation by University of Oklahoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07080788University of OklahomaOklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Smoking Cessation by University of Oklahoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the proposed project is to evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely benefit from financial incentives for smoking cessation. The investigators have previously combined technologies including 1) portable carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to confirm participant identity during breath sample submissions, and 3) remote delivery of incentives automatically triggered by biochemical confirmation of self-reported abstinence. This automated CM approach will be evaluated in a randomized controlled trial that includes 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to either telephone counseling and nicotine replacement therapy (standard care [SC]) or SC plus a mobile financial incentives intervention (CM) for biochemically-confirmed abstinence. Participants will be followed for 26 weeks after a scheduled quit attempt. Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit will be the primary outcome variable. Cost-effectiveness will be evaluated to inform policy-related decisions. Potential mobile CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future versions of the intervention.
The primary purpose of the proposed project is to evaluate an automated smartphone-based CM approach that will allow socioeconomically disadvantaged adults to earn financial incentives for smoking cessation without requiring in-person attendance for abstinence verification. The investigators have combined technologies: 1) low-cost carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to verify the identity of participants while they provide a breath sample, and 3) remote and automated delivery of incentives to a credit card triggered by biochemical confirmation of self-reported smoking abstinence. This CM approach will be evaluated in a randomized controlled trial of 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to telephone counseling plus nicotine replacement therapy (standard care [SC]) or SC plus a 12-week smartphone-based financial incentives intervention (CM). Participants will be followed for 26 weeks after a scheduled quit attempt, which is 14 weeks after incentives have ended. Cost-effectiveness will be evaluated to inform policy and health care decisions. Potential CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement will be identified to optimize future versions of the intervention. The specific aims are: 1) to evaluate the impact of an automated, mobile phone-based CM approach relative to SC on smoking cessation among socioeconomically disadvantaged adults, 2) to compare the cost-effectiveness of two smoking cessation interventions (CM vs. SC), and 3) to identify mobile CM treatment mechanisms such as motivation to quit, self-efficacy for quitting, and treatment engagement/adherence. The proposed study will evaluate an intervention approach that increases the reach of a potentially effective and cost-effective smoking cessation intervention for socioeconomically disadvantaged smokers. This proposed study is also going to be conducting recruitment nationwide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
1) do not meet the specified inclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
Other: Standard Care (SC)
CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
Behavioral: Automated Mobile Contingency Management (CM) · Other: Standard Care (SC)
Financial incentives contingent upon smoking abstinence
Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 26 weeks post-quit.
Time frame: 26 weeks post-quit-date
Cost-effectiveness
The incremental cost effectiveness ratio (ICER) calculated as the difference in mean costs between the new (CM) and standard treatment (SC) divided by the difference in mean effectiveness between the two, estimates additional resources needed to achieve an increase of one unit of effectiveness. The ICER is then compared with published threshold values for cost-effective interventions. The cost model will include all necessary personnel, hardware, and material costs.
Time frame: 26 weeks post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 12 weeks post-quit-date.
Time frame: 12 week post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 8 weeks post-quit-date.
Time frame: 8 weeks post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 4 weeks post-quit-date.
Time frame: 4 weeks post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days)
Number of participants with carbon monoxide-verified 30-day point prevalence abstinence at 26 weeks post-quit-date.
Time frame: 26 weeks post-quit-date
| Milestone | Standard Care (SC) | Contingency Management (CM) |
|---|---|---|
| Started | 267 | 265 |
| Completed | 220 | 217 |
| Not completed | 47 | 48 |
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 26 weeks post-quit.
| Participants | Standard Care (SC) | Contingency Management (CM) |
|---|---|---|
| Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days) | 35 | 50 |
The incremental cost effectiveness ratio (ICER) calculated as the difference in mean costs between the new (CM) and standard treatment (SC) divided by the difference in mean effectiveness between the two, estimates additional resources needed to achieve an increase of one unit of effectiveness. The ICER is then compared with published threshold values for cost-effective interventions. The cost model will include all necessary personnel, hardware, and material costs.
Results for this outcome have not been posted.
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 12 weeks post-quit-date.
| Participants | Standard Care (SC) | Contingency Management (CM) |
|---|---|---|
| Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days) | 39 | 55 |
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 8 weeks post-quit-date.
| Participants | Standard Care (SC) | Contingency Management (CM) |
|---|---|---|
| Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days) | 35 | 64 |
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 4 weeks post-quit-date.
| Participants | Standard Care (SC) | Contingency Management (CM) |
|---|---|---|
| Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days) | 54 | 71 |
Number of participants with carbon monoxide-verified 30-day point prevalence abstinence at 26 weeks post-quit-date.
| Participants | Standard Care (SC) | Contingency Management (CM) |
|---|---|---|
| Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days) | 32 | 46 |
Collected over 27 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard Care (SC) | 0/267 (0%) | 0/267 (0%) | 8/267 (3%) |
| Contingency Management (CM) | 0/265 (0%) | 0/265 (0%) | 6/265 (2.3%) |
| Event | Standard Care (SC) | Contingency Management (CM) |
|---|---|---|
| Possible NRT side effectsGeneral disorders | 3/267 | 2/265 |
| Sleep DisturbanceGeneral disorders | 1/267 | 1/265 |
| Payment ErrorProduct Issues | 1/267 | 1/265 |
| Breath Monitor Device ProblemsProduct Issues | 1/267 | 1/265 |
| Elevated PHQ score (depression)Psychiatric disorders | 0/267 | 1/265 |
| Elevated Blood PressureCardiac disorders | 1/267 | 0/265 |
| General Study ProcessesGeneral disorders | 1/267 | 0/265 |
| Age, Continuous(years) | Standard Care (SC) | Contingency Management (CM) | Total |
|---|---|---|---|
| Mean | 53.69 ± 11.45 | 53.11 ± 12.23 | 53.40 ± 11.83 |
| Sex: Female, Male(Participants) | Standard Care (SC) | Contingency Management (CM) | Total |
|---|---|---|---|
| Female | 186 | 183 | 369 |
| Male | 81 | 82 | 163 |
| Ethnicity (NIH/OMB)(Participants) | Standard Care (SC) | Contingency Management (CM) | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 16 | 37 |
| Not Hispanic or Latino | 246 | 249 | 495 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Standard Care (SC) | Contingency Management (CM) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 7 | 16 |
| Asian | 5 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 54 | 63 | 117 |
| White | 177 | 180 | 357 |
| More than one race | 21 | 12 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Annual Household Income(Participants) | Standard Care (SC) | Contingency Management (CM) | Total |
|---|---|---|---|
| <$21,000 | 162 | 155 | 317 |
| >=$22,000 | 105 | 110 | 215 |
| Cigarettes Smoked Per Day (pre-quit)(Cigarettes per day) | Standard Care (SC) | Contingency Management (CM) | Total |
|---|---|---|---|
| Mean | 17.61 ± 8.78 | 17.51 ± 8.77 | 17.56 ± 8.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified data will be made available to investigators upon request, after publication of the primary study findings, and with a data-sharing agreement that specifies the investigator(s) will 1) use the data only for research purposes and not to identify any individual participant, 2) store the data on a secure device (e.g., encrypted, password-protected), and 3) destroy or return the data after completion of the analyses.
Supporting information: Study protocol, Informed consent form
Time frame: De-identified data will be made available to investigators upon request after publication of the primary study findings.
Access criteria: Data sharing agreement
Ran from Nov 2022 to primary completion in Sep 2025, 34 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 34 months is above that.
Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.